// App-Quantinova.ai

FRI0087 : DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA

Researchers

Presenter

  • V. Bykerk

Principal Investigators

  • A. B. Gottlieb

  • K. Reich

  • Y. Tanaka

  • K. Winthrop

  • C. Popova

  • N. Tilt

  • A. Blauvelt

Medical Centers

  • Hospital for Special Surgery Main Hospital, New York, United States of America

  • Icahn School of Medicine at Mount Sinai Hospital - New York - United States of America

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Oregon Health & Science University, Portland, United States of America

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Slough, UK Slough United Kingdom

  • Oregon Medical Research Center, Portland, United States

Locations

  • United States

  • Germany

  • Japan

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved